OzemPic use among adolescents is the decrease and parents receive severe notice from experts

It is the hot correction that Hollywood brought, and now secondary, by storm.

Ozempic and others called “miracle” weight loss medicines are being prescribed to adolescents in record numbers, with recipes among children from 12 to 17 years old who jump 50% by 2024, according to Truveta.

Another study by the Evernorth Research Institute, according to Reuters, was a 68% increase in use among adolescents in general.

But although thin features like Wegovy can reduce waist, some experts say that parents should pump the brakes, before turning their children into pin pillows.

Dr. Robert Siegel, a pediatrician at Cincinnati Children’s Hospital, did not make words, saying to the news agency: “These medicines are likely to be needed for a long time to maintain weight.”

He added that “we only have a relatively short -term experience with them.”

In other words, we have barely scratched the surface on what these medicines could do for the cultivation of bodies, and children could be stuck in life.

Rise in teen recipes comes after Wegovy was approved for adolescents in late 2022.

Since then, desperate families to combat the obesity epidemic-which affects 1 in 4 American adolescents-have become GLP-1 medicines in increasing numbers.

“It is promising that younger people use these medicines, but it is still a very small percentage of patients with severe obesity that access them,” Dr. Cate Varney, Director of Obesity Medicine of the University of Virginia Health System, told Reuters.

“When changes in lifestyle are only inadequate, we need these additional tools.”

Still, the new tools include a lot of fine printing.

“Medicines may need to be used indefinitely,” Siegel said, noting that most pediatricians do not have training (or equipment) to monitor long -term effects such as muscle loss or development delays.

Novo Nordisk, the manufacturer of Ozempic and Wegovy, insists that there is no reason for panic.

The company said in a statement that the semaglutide “did not seem to affect the growth or the publisher development” in the clinical trials for adolescents.

“We are sure in the safety and efficiency demonstration of our GLP-1 medicines,” Novo added.

Eli Lilly, whose drug is tested for adolescent use, echoed this position, according to Reuters.

“So far there is no evidence that suggests a deterioration in growth or metabolism,” the company said.

But that is not enough to calm critics. United States Secretary of Health, Robert F. Kennedy Jr., struck the tendency as a sign of the “overdiedicalization of our children”, citing a lack of long -term security data and possible threats to metabolism and development.

With weight loss features that seem like a long-distance commitment to a quick solution, some doctors say that adolescents should focus on old school strategies before resorting to syringes.

As reported earlier, a Survey of the Digital Health Platform Tebra found that 37% of young Americans in this age group plan to leave the gym and go to the pharmacy instead of, passing to Ozempic drugs, Wegovy and other GLP-1 to achieve their weight loss goals.

Although Gen Z is the most eager to jump into the injection cart, the elderly is really more confident in the effectiveness of the drugs, with 72% of the baby boomers who say they work better than traditional methods.

However, mania has a dark side: some users have become shady, even dangerous methods, including counterfeit medicines and non -prescribed use, causing new fears of proper addiction and lack of supervision.